| Targeting C-reactive protein for the treatment of cardiovascular disease MB Pepys, GM Hirschfield, GA Tennent, J Ruth Gallimore, MC Kahan, ... Nature 440 (7088), 1217-1221, 2006 | 894 | 2006 |
| Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis MB Pepys, J Herbert, WL Hutchinson, GA Tennent, HJ Lachmann, ... Nature 417 (6886), 254-259, 2002 | 640 | 2002 |
| Virus control of cell metabolism for replication and evasion of host immune responses MMB Moreno-Altamirano, SE Kolstoe, FJ Sánchez-García Frontiers in cellular and infection microbiology 9, 95, 2019 | 102 | 2019 |
| Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component SE Kolstoe, BH Ridha, V Bellotti, N Wang, CV Robinson, SJ Crutch, ... Proceedings of the National Academy of Sciences 106 (18), 7619-7623, 2009 | 87 | 2009 |
| Trapping of palindromic ligands within native transthyretin prevents amyloid formation SE Kolstoe, PP Mangione, V Bellotti, GW Taylor, GA Tennent, S Deroo, ... Proceedings of the National Academy of Sciences 107 (47), 20483-20488, 2010 | 82 | 2010 |
| Structure of human porphobilinogen deaminase at 2.8 Å: the molecular basis of acute intermittent porphyria R Gill, SE Kolstoe, F Mohammed, A Al D-Bass, JE Mosely, M Sarwar, ... Biochemical Journal 420 (1), 17-25, 2009 | 80 | 2009 |
| Increased personal protective equipment litter as a result of COVID-19 measures KP Roberts, SC Phang, JB Williams, DJ Hutchinson, SE Kolstoe, J de Bie, ... Nature Sustainability 5 (3), 272-279, 2022 | 61 | 2022 |
| Structural basis of ligand specificity in the human pentraxins, C‐reactive protein and serum amyloid P component H Mikolajek, SE Kolstoe, VE Pye, P Mangione, MB Pepys, SP Wood Journal of Molecular Recognition 24 (2), 371-377, 2011 | 51 | 2011 |
| Transient Expression in HEK 293 Cells: An Alternative to E. coli for the Production of Secreted and Intracellular Mammalian Proteins JE Nettleship, PJ Watson, N Rahman-Huq, L Fairall, MG Posner, ... Insoluble Proteins: Methods and Protocols, 209-222, 2015 | 46 | 2015 |
| Exempting low-risk health and medical research from ethics reviews: comparing Australia, the United Kingdom, the United States and the Netherlands AM Scott, S Kolstoe, MCC Ploem, Z Hammatt, P Glasziou Health research policy and systems 18, 1-8, 2020 | 42 | 2020 |
| Measuring inconsistency in research ethics committee review S Trace, SE Kolstoe BMC medical ethics 18, 1-10, 2017 | 41 | 2017 |
| Drug targets for amyloidosis SE Kolstoe, SP Wood Biochemical Society Transactions 38 (2), 466-470, 2010 | 34 | 2010 |
| Coronavirus face masks: an environmental disaster that might last generations KP Roberts, C Bowyer, S Kolstoe, S Fletcher The Conversation 14, 2020 | 26 | 2020 |
| Can UK NHS research ethics committees effectively monitor publication and outcome reporting bias? R Begum, S Kolstoe BMC Medical Ethics 16, 1-5, 2015 | 17 | 2015 |
| Interaction of serum amyloid P component with hexanoyl bis (D-proline)(CPHPC) SE Kolstoe, MC Jenvey, A Purvis, ME Light, D Thompson, P Hughes, ... Acta Crystallographica Section D: Biological Crystallography 70 (8), 2232-2240, 2014 | 17 | 2014 |
| Registration audit of clinical trials given a favourable opinion by UK research ethics committees C Denneny, S Bourne, SE Kolstoe BMJ open 9 (2), e026840, 2019 | 15 | 2019 |
| Improving research ethics review and governance can improve human health P Glasziou, AM Scott, I Chalmers, SE Kolstoe, HT Davies Journal of the Royal Society of Medicine 114 (12), 556-562, 2021 | 11 | 2021 |
| Reviewing code consistency is important, but research ethics committees must also make a judgement on scientific justification, methodological approach and competency of the … S Trace, S Kolstoe Journal of medical ethics 44 (12), 874-875, 2018 | 11 | 2018 |
| Perspectives for drug intervention in amyloid diseases S Kolstoe, S Wood Current Drug Targets 5 (2), 151-158, 2004 | 10 | 2004 |
| UK Research Ethics Committee’s review of the global first SARS-CoV-2 human infection challenge studies H Davies Journal of Medical Ethics 49 (5), 322-324, 2023 | 8 | 2023 |
Mark PepysAdresse e-mail validée de ucl.ac.uk
